![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics (PK) and Safety of Dolutegravir (DTG) in Subjects With Severe Renal Impairment and Healthy Controls
|
|
|
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO
Stephen Weller,1 Julie Borland,1 Shuguang Chen,1 Mark Johnson,1 Paul Savina,1 Brian Wynne,2 Stephen Piscitelli1
1-2GlaxoSmithKline, 1Research Triangle Park, NC, USA; 2Upper Providence, PA, USA
![ICAAC1.gif](../images/091613/091613-6/ICAAC1.gif)
![ICAAC2.gif](../images/091613/091613-6/ICAAC2.gif)
![ICAAC3.gif](../images/091613/091613-6/ICAAC3.gif)
![ICAAC4.gif](../images/091613/091613-6/ICAAC4.gif)
![ICAAC5.gif](../images/091613/091613-6/ICAAC5.gif)
![ICAAC6.gif](../images/091613/091613-6/ICAAC6.gif)
![ICAAC7.gif](../images/091613/091613-6/ICAAC7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|